Bagneux, France
Bagneux, France

Time filter

Source Type

Patent
DBV Technologies | Date: 2016-12-01

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.


— Market Pipeline Report Peanut Allergy Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Oncology) pipeline landscape. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 23 Tables and 11 Figures, 12 Company Profiles, Spread across 84 Pages Report Available at http://www.reportsnreports.com/reports/992907-peanut-allergy-pipeline-review-h1-2017.html . Peanut Allergy market companies are Adverum Biotechnologies Inc, Aimmune Therapeutics Inc, Alfacyte Ltd, Allergy Therapeutics Plc,AnaptysBio Inc, ASIT Biotech SA, Astellas Pharma Inc, BioLingus AG,DBV Technologies SA,HAL Allergy BV, Intrommune Therapeutics, Sanofi. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992907 The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology). • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology) Reasons to buy • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992907-peanut-allergy-pipeline-review-h1-2017.html


Patent
DBV Technologies | Date: 2017-06-14

The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen.


Patent
DBV Technologies | Date: 2017-02-03

The invention relates to novel compositions and methods for diagnosing or treating food allergies. The invention particularly discloses new approaches for delivering food allergens to allergic patients by oral administration of formulations which dissolve and release proteins in the stomach. The invention allows the treatment of food allergies by delivering food allergens to the gut immune system with controlled exposure of the esophagus or oral cavity. The invention also allows to perform food challenges to assess the threshold of clinical reactivity without exposing the esophagus and oral cavity. The invention may be used in any subject, particularly human subjects, and is applicable to any food allergen.


Patent
DBV Technologies | Date: 2016-06-16

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.


Patent
DBV Technologies | Date: 2015-01-14

The present invention relates to compositions and methods for improving a subject condition by epicutaneous immunobalancing. The invention shows that particular regulatory T cells can be induced and maintained in a subject by epicutaneous treatment, thereby causing a substantial improvement in a subject condition. The invention may be used in a preventive context, to improve the immunobalance of a subject and avoid the onset or development of diseases, as well as in a therapeutic context, to improve a subject recovery. The invention is particularly suitable to prevent or treat a proliferative or autoimmune disease. The invention may be used in any mammalian subject, preferably in human subjects, including children and adults.


Patent
DBV Technologies | Date: 2013-02-04

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.


Patent
DBV Technologies | Date: 2012-10-12

The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen.


Patent
DBV Technologies, French Institute of Health and Medical Research | Date: 2016-04-22

The present invention relates to the treatment of haemophilia. More specifically, the invention relates to a new method of inducing an immune tolerance against at least one blood factor used to treat haemophilia through the epicutaneous route by application of a skin patch device comprising a blood factor in order to continue haemophilia treatment. The present invention also relates to the skin patch device containing Factor VIII.


Patent
DBV Technologies | Date: 2013-08-14

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.

Loading DBV Technologies collaborators
Loading DBV Technologies collaborators